- Home
- SANM vs MRUS Comparison
SANM vs MRUS Comparison
Compare SANM & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANM
- MRUS
- Stock Information
- Founded
- SANM 1980
- MRUS 2003
- Country
- SANM United States
- MRUS Netherlands
- Employees
- SANM N/A
- MRUS N/A
- Industry
- SANM Electrical Products
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- SANM Technology
- MRUS Health Care
- Exchange
- SANM Nasdaq
- MRUS Nasdaq
- Market Cap
- SANM 4.5B
- MRUS 4.1B
- IPO Year
- SANM 1993
- MRUS 2016
- Fundamental
- Price
- SANM $116.98
- MRUS $67.25
- Analyst Decision
- SANM Hold
- MRUS Strong Buy
- Analyst Count
- SANM 2
- MRUS 12
- Target Price
- SANM $94.50
- MRUS $91.00
- AVG Volume (30 Days)
- SANM 957.4K
- MRUS 630.0K
- Earning Date
- SANM 07-28-2025
- MRUS 08-05-2025
- Dividend Yield
- SANM N/A
- MRUS N/A
- EPS Growth
- SANM 21.02
- MRUS N/A
- EPS
- SANM 4.67
- MRUS N/A
- Revenue
- SANM $8,049,495,000.00
- MRUS $56,228,000.00
- Revenue This Year
- SANM $9.18
- MRUS $67.27
- Revenue Next Year
- SANM $7.43
- MRUS $0.49
- P/E Ratio
- SANM $25.05
- MRUS N/A
- Revenue Growth
- SANM 5.88
- MRUS 59.77
- 52 Week Low
- SANM $62.76
- MRUS $33.19
- 52 Week High
- SANM $125.76
- MRUS $67.59
- Technical
- Relative Strength Index (RSI)
- SANM 58.12
- MRUS 64.48
- Support Level
- SANM $117.50
- MRUS $63.21
- Resistance Level
- SANM $125.76
- MRUS $67.59
- Average True Range (ATR)
- SANM 5.10
- MRUS 2.24
- MACD
- SANM -0.20
- MRUS -0.28
- Stochastic Oscillator
- SANM 59.74
- MRUS 93.75
About SANM Sanmina Corporation
Sanmina Corp is a provider of integrated manufacturing solutions, components, and after-market services to original equipment manufacturers in the communications networks, storage, industrial, defense and aerospace end markets. The operations are managed as two businesses: Integrated Manufacturing Solutions, which consists of printed circuit board assembly and represents a majority of the firm's revenue; and Components, Products, and Services, which includes interconnect systems and mechanical systems. The firm generates revenue primarily in the United States, China, and Mexico, but has a presence around the world.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.